This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05426/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05426/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05426/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05426
rdf:type
n3:Drug
n3:description
Talactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
n3:generalReferences
# Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, Armstrong DG, Reese A, Yankee EW, Veves A: Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17188087
n3:group
investigational
n3:indication
Investigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
owl:sameAs
n6:DB05426
dcterms:title
talactoferrin alpha
adms:identifier
n9:DB05426 n10:192716 n11:167235
n3:mechanismOfAction
Oral talactoferrin stimulated the production of the immunostimulatory cytokine IL-18 in mice, increasing IL-18 levels both in the gut and in systemic circulation. Oral talactoferrin was also shown to stimulate the activity of NK cells and to increase the production and activity of key circulating immune cells.
n3:IUPAC-Name
n4:271B4356-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B435C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B435B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4358-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4359-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B435A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4354-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4352-363D-11E5-9242-09173F13E4C5 n4:271B4355-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4353-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4362-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4363-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B435D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B435E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4360-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B435F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4361-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4368-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B436A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B436B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4367-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4366-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4369-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4357-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4364-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4365-363D-11E5-9242-09173F13E4C5